Bay City Capital — Full Portfolio

BiotechCambridge, US

James G. McArthur(Executive Officer, Director)Christoph M. Adams(Executive Officer, Director)

BoardSara Nayeem(Director)Barbara Dalton(Director)David Mott(Director)Robert Hopfner(Director)

Board seatCarl Goldfischer· per SEC Form D

Co-investorsNew Enterprise Associates (NEA)RA CapitalArix BioscienceOrbiMed

BiotechLouisville, US

Nevan Elam(Executive Officer, Director)Sankaram Mantripragada(Executive Officer)Nevan Charles Elam(Executive Officer, Director)Morgan Lynn Fields(Executive Officer)

BoardHoyoung Huh(Director, Executive Officer)Barry Sherman(Director)

Gossamer Bio is a clinical-stage biopharmaceutical company developing seralutinib, an investigational drug candidate for treating pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.

BiotechDigital HealthMedical DevicesSan Diego, US

Faheem Hasnain(Executive Officer, Director)inChristian Waage(Executive Officer)inSheila Gujrathi, MD(Founder)inBryan Giraudo(Executive Officer)Laura Carter, Ph.D.(Executive Officer)Joshua Bilenker, M.D.(Director)

Co-investorsARCH Venture PartnersEcoR1 CapitalFoothill VenturesNew Enterprise Associates (NEA)Samsara BioCapital

Nextcure is a clinical-stage biopharmaceutical company developing immunotherapies targeting IO pathways, with a focus on oncology applications.

BiotechBeltsville, US

Michael Richman(Executive Officer, Director)Timothy Mayer(Executive Officer)Udayan Guha(Executive Officer)Steven P. Cobourn(Executive Officer)Sourav Kundu(Executive Officer)Kevin Shaw(Executive Officer)

Co-investorsCanaan PartnersLAVLilly Asia VenturesPfizer Venture InvestmentsQuan CapitalSofinnova Ventures+2 more

BiotechSouth Plainfield, US

Stuart W. Peltz(Executive Officer, Director)Allan S. Jacobson(Director)Mark E. Boulding(Executive Officer)Christine Utter(Executive Officer)Marcio Souza(Executive Officer)Neil Almstead(Executive Officer)

Co-investorsLongwood Fund

Twist Bioscience develops a silicon-based synthetic DNA manufacturing platform that produces high-quality DNA, genes, and NGS reagents for customers in medicine, agriculture, and industrial chemicals.

BiotechDeep TechSemiconductorsSouth San Francisco, US

Emily Marine Leproust(Executive Officer, Director, Promoter)William Charles Banyai(Executive Officer, Director, Promoter)Bill James Peck(Executive Officer, Promoter)Emily Leproust(Founder)in

BoardKeith Crandell(Director)Paul Conley(Director)in

Co-investors+ND Capital3E Bioventures CapitalARCH Venture PartnersAsset Management CompanyBlack Opal VenturesDentsu Ventures+7 more

Xilio Therapeutics is a clinical-stage biotechnology company developing masked immuno-oncology therapies that use protein engineering to remain inactive until activated by tumor-specific proteases within the tumor microenvironment.

BiotechHealthtechWaltham, US

Rene Russo(Executive Officer, Director)inJoseph Farmer(Executive Officer)Timothy Clackson(Executive Officer)Paul Clancy(Director)Daniel Curran(Director)Nancy Hong(Director)

Co-investorsBain Capital Life SciencesF-Prime CapitalM VenturesMRL Ventures FundRA CapitalRiverVest Venture Partners+4 more

HealthtechSt Paul, US

Dan W Gladney(Executive Officer, Director)Scott P Youngstrom(Executive Officer)Rajesh Nihalani(Executive Officer)Peter M DeLange(Executive Officer)Paul F Hickey(Executive Officer)Naqeeb A Ansari(Executive Officer)

Board seatCarl Goldfischer· per SEC Form D

HealthtechSan Diego, US

John Hutchinson(Executive Officer)Vanessa Jacoby(Executive Officer)Robert Williamson(Executive Officer, Director, Promoter)

BoardRupert Vessey(Director)

Board seatCarl Goldfischer· per SEC Form D · $3M raise · filed Sep 2016

BiotechSacramento, US

George Barry(Co-Founder of Issuer)Philip H. Coelho(Chief Technology Officer and Co-Founder of Issuer)Chuck Novak(Vice President and Chief Financial Officer of the Issuer)William Gerber(Chief Executive Officer and President of Issuer)

BoardWoodrow A. Myers, Jr.(Director)

Board seatCarl Goldfischer· per SEC Form D

BiotechSouth San Francisco, US

Wendye Robbins(Executive Officer, Director)

BoardLuke Evnin(Director)inCameron Wheeler(Director)Peter van Vlasselaer(Director)Elaine Jones(Director)William Slattery(Director)

Co-investorsOUP (Osage University Partners)Pfizer Venture Investments+ND CapitalMPM BioImpact

Co-investorsNew Enterprise Associates (NEA)

BiotechChelsea, US

RICHARD BATYCKY(Executive Officer)GLENN BATCHELDER(Director)BRYAN STUART(Executive Officer)MARK IWICKI(Executive Officer, Director)MARTIN FREED(Executive Officer)

BoardROB HOPFNER(Director)

Co-investorsCanaan PartnersSofinnova VenturesLongitude CapitalOrbiMedRA Capital

Gilead Sciences is a biopharmaceutical company that develops medicines across virology, oncology, and inflammation, with more than 25 medicines offered globally and a clinical pipeline spanning these three therapeutic areas.

BiotechHealthtechNewark, US

Harold Van Wart, Ph. D.(Executive Officer, Director)Pol Boudes(Executive Officer)Charles A. McWherter, Ph. D.(Executive Officer)Sujal Shah(Executive Officer)

BoardCarl Goldfischer, M.D.(Director)Kurt von Emster(Director)

Co-investorsAvoro Capital AdvisorsForesite CapitalVantagePoint Capital Partners

HealthtechMenlo Park, US

THOMAS G. WIGGANS(Executive Officer, Director)EUGENE A. BAUER(Executive Officer, Director)Christopher M. Griffith(Executive Officer, Promoter)Luis C. Pena(Executive Officer, Promoter)Thomas G. Wiggans(Executive Officer, Director, Promoter)Eugene A. Bauer(Executive Officer, Director, Promoter)

Co-investorsAisling CapitalCanaan PartnersForesite CapitalNew Enterprise Associates (NEA)Fidelity InvestmentsQiming Healthcare+1 more

David Minkinin

Co-investorsMillennium Technology Value PartnersThreshold Ventures

Nexoplex Bio develops immunotherapies that target tumor cells through recognition of HLA-peptide complexes using multi-specific antibodies, addressing tumor types including lung, gastric, esophageal, head and neck, cervical cancers, and lung squamous cell carcinoma.

BiotechDeep TechHealthtechSan Carlos, US

Wayne(CEO)Rachel(VP of Operations)

Co-investorsGV (Google Ventures)LAVLilly Asia Ventures

Addressing unmet needs in gastroenterology and hepatology.

BiotechBrisbane, US

Bo Jesper Hansen(Director)Christine Nash(Executive Officer)Natalie Holles(Executive Officer)Jake R. Nunn(Director)Bijan Salehizadeh(Director)Daniel G. Welch(Director)

Co-investorsSofinnova Ventures

Biopharmaceutical company developing innovative therapies for chronic diseases using proprietary drug delivery systems.

BiotechBoston, US

James Ahlers(Executive Officer)John Yee(Executive Officer)Sunita Zalani(Executive Officer)Raymond T. Keane(Executive Officer)Thomas Alessi(Executive Officer)Owen Hughes, Jr.(Executive Officer)

Co-investorsCycad Group LLCForesite CapitalNXT Ventures

BiotechWatham, US

Kenneth Kornman(Executive Officer, Director)Stephen DiPalma(Executive Officer)

BoardJoseph Landstra(Director)Lionel Carnot(Director)Dayton Misfeldt(Director)James Weaver(Director)

Iterum Therapeutics develops anti-infective compounds to treat infections caused by multi-drug resistant pathogens.

BiotechDigital HealthHealthtechMedical DevicesDublin, US

Michael W. Dunne(Executive Officer, Promoter)Corey N. Fishman(Executive Officer, Director, Promoter)Judith M. Matthews(Executive Officer, Promoter)Jeff Schaffnit(Executive Officer)

BoardBrenton K. Ahrens(Director)Ronald M. Hunt(Director)

Co-investorsCanaan PartnersSofinnova VenturesFrazier Life SciencesSofinnova Venture Partners

KBP is a biotechnology research and development organization that discovers and develops new therapies for unmet medical needs.

Biotech

Co-investorsHM Venture Partners

BiotechSouth San Francisco, US

John F. Fowler(Executive Officer, Director)Christopher J. Kirk(Executive Officer, Director)

BoardDr. Gerald Chan(Director)Dr. Jean-Pierre Sommadossi(Director)

Co-investorsChiesi VenturesPappas CapitalSolasta Ventures

Madrigal is a biopharmaceutical company developing therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious progressive liver disease.

BiotechHealthtech

Co-investorsAvoro Capital Advisors

Nevro develops spinal cord stimulation (SCS) systems for the treatment of chronic pain, including FDA-approved indications for painful diabetic neuropathy and non-surgical back pain.

Digital HealthHealthtechMedical Devices

Co-investorsNew Enterprise Associates (NEA)

Medical DevicesNew Jersey, US

Co-investorsF-Prime CapitalSofinnova Ventures

Oculis is a biopharmaceutical company developing pharmaceutical drug products, with a focus on ophthalmic and eye disease treatments.

BiotechHealthtechMedical DevicesBoston, CH

Riad Sherif(Chief Executive Officer)

Co-investorsBrunnur Ventures GPVI Partners

Co-investorsNew Enterprise Associates (NEA)

Firmenich is a co-creation and innovation partner specializing in nutrition, health, and beauty ingredients and solutions.

ConsumerHealthtechNew MaterialsGeneva, CH

Gilbert Ghostinein

Co-investorsProspect Venture PartnersRho Ventures

Co-investorsVenrock

Co-investorsF-Prime Capital

Tria Beauty makes at-home laser devices for consumers, including the Tria 4X hair removal laser and the FRX skin rejuvenating fractional laser for reducing fine lines and improving pigmentation.

ConsumerDirect to ConsumerHealthtechWellness & FitnessDublin, US

TOBIN C. ISLAND(Executive Officer)KEVIN J. APPELBAUM(Executive Officer, Director)DEREK YUNG(Executive Officer)DANIKA HARRISON(Executive Officer)JIYOUNG CHOI(Executive Officer)CHARLES BRACHER(Director)

Co-investorsAisling CapitalIncubic Management LLC

Developing oncology therapeutics for viral-induced tumors; went public February 2021 (VIRX).

Co-investorsaMoonLatterell Venture Partners

Vivaldi Biosciences develops nasal-spray vaccines built on its Delta NS1 platform, a replication-deficient vaccine vector derived from a genetically modified influenza virus, for protection against epidemic and pandemic respiratory diseases.

BiotechHealthtech

BiotechAustin, US

Steven Prestrelski(Executive Officer)Douglas Baum(Executive Officer, Director)Poul Strange(Executive Officer)Yash Sabharwal(Executive Officer)John Kinzell(Executive Officer, Director)Timothy Sullivan(Director)